Table. 2.

Recurrence and survival patterns between two treatment groups

Before matching After matching
Adjuvant (n = 107) No adjuvant (n = 123) p-value Adjuvant (n = 70) No adjuvant (n = 70) p-value
Recurrence 49 (45.8) 52 (42.3) 0.592 29 (41.4) 31 (44.3) 0.733
Controlled 58 (54.2) 71 (57.7) 41 (58.6) 39 (55.7)
Recurrence as per T stage group 0.014* 0.347
T1-T2 6 (12.2) 17 (32.7) 4 (13.8) 2 (6.5)
T3-T4 43 (87.8) 35 (67.3) 25 (86.2) 29 (93.5)
Distant failure 23 (21.5) 37 (30.1) 0.064 14 (20.0) 24 (34.3) 0.070
LR failure 12 (11.2) 5 (4.1) 7 (10.0) 2 (2.9)
LR + distant failure 10 (9.3) 7 (5.7) 4 (5.7) 3 (4.3)
Exact site not known 4 (3.7) 3 (2.4) 4 (5.7) 2 (2.9)
Time of recurrence 0.492 0.595
≤ 6 mon 6 (5.6) 3 (2.4) 4 (5.7) 3 (4.3)
7 mon to ≤ 2 yr 26 (24.3) 29 (23.6) 18 (25.7) 15 (21.4)
> 2 yr to ≤ 5 yr 17 (15.9) 18 (14.6) 7 (10.0) 12 (17.1)
> 5 yr 0 (0) 2 (1.6) 0 (0) 1 (1.4)
Alive 67 (62.6) 63 (51.2) 0.082 48 (68.6) 30 (42.9) 0.002*
Dead 40 (37.4) 60 (48.8) 22 (31.4) 40 (57.1)
Median RFS in months (95% CI) 38 (29–51) 59 (42–72) 0.195 40 (29–51) 53 (29–70) 0.797
Median OS in months (95% CI) 54 (40–71) 54 (36–65) 0.624 71 (40–71) 36 (26–63) 0.087

Values are presented as number (%) unless otherwise indicated.

LR, locoregional; RFS, recurrence-free survival; OS, overall survival; CI, confidence interval.

*Represents p-value significant.

Ann Hepatobiliary Pancreat Surg 2024;28:371-80 https://doi.org/10.14701/ahbps.24-032
© 2024 Ann Hepatobiliary Pancreat Surg